The up-regulation of ATAD2 in a variety of diverse cancer types suggests that pharmacological inhibition of its bromodomain function could be beneficial in cancer therapies, and it is currently under investigation by both pharmaceutical companies and research institutes alike [19,20,21]. This evidence concerns the gene ATAD2 and cancer.